Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03631836
Title	Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma (MARELLE01)
Acronym	MARELLE01
Recruitment	Unknown status
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Assistance Publique Hopitaux De Marseille
Indications	glioblastoma
Therapies	Andecaliximab + Bevacizumab
Age Groups:	adult \| senior
Covered Countries	FRA